دورية أكاديمية
أعرض في EDS

Anticholinergic Burden in Patients Treated for Overactive Bladder: Second-Line Therapy with Tibial Nerve Stimulation as a Solution.

التفاصيل البيبلوغرافية
العنوان: Anticholinergic Burden in Patients Treated for Overactive Bladder: Second-Line Therapy with Tibial Nerve Stimulation as a Solution.
المؤلفون: Satyadev N; Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Rd S, Jacksonville, FL, 3224, USA. satyadev.nihal@mayo.edu.; Department of Medicine, University of Medicine and Health Sciences, Basseterre, St. Kitts and Nevis. satyadev.nihal@mayo.edu., Ameen M; Department of Medicine, Ross University, Bridgeton, Barbados, USA., Do TH; Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA., Wang H; Department of Obstetrics and Gynecology, Detroit Medical Center, Bloomfield Hills, MI, USA.
المصدر: International urogynecology journal [Int Urogynecol J] 2024 Jul; Vol. 35 (7), pp. 1375-1379. Date of Electronic Publication: 2024 May 03.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: England NLM ID: 101567041 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-3023 (Electronic) Linking ISSN: 09373462 NLM ISO Abbreviation: Int Urogynecol J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Springer
مواضيع طبية MeSH: Urinary Bladder, Overactive*/therapy , Urinary Bladder, Overactive*/drug therapy , Tibial Nerve* , Cholinergic Antagonists*/adverse effects , Cholinergic Antagonists*/therapeutic use , Transcutaneous Electric Nerve Stimulation*, Humans ; Female ; Practice Guidelines as Topic
مستخلص: Overactive bladder (OAB) is a highly prevalent condition with significant associated comorbidities. Current management guidelines suggest the utilization of anticholinergic medication as a second line after nonpharmacological treatment. Tibial nerve stimulation (TNS), which has previously been thought to have been expensive and inaccessible, was relegated to a third-line therapy. However, given the recently discovered association between anticholinergic medication use and dementia as well as the recent FDA approval of transcutaneous tibial nerve stimulation (TTNS), there may be a need to revisit management guidelines. In this commentary, we identify the two types of TNS, percutaneous tibial nerve stimulation (PTNS) and TTNS and compare them with anticholinergics. By considering their respective efficacies, side-effects profiles, and associated costs, we make the case in this commentary for an update to guidelines that includes TNS as second-line OAB management ahead of anticholinergic medication.
(© 2024. The International Urogynecological Association.)
References: Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/nau.22295. (PMID: 10.1002/nau.2229522847394)
Powell LC, Szabo SM, Walker D, Gooch K. The economic burden of overactive bladder in the United States: a systematic literature review. Neurourol Urodyn. 2018;37(4):1241–9. https://doi.org/10.1002/nau.23477 . (PMID: 10.1002/nau.2347729331047)
Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–63. https://doi.org/10.1097/JU.0000000000000309 . (PMID: 10.1097/JU.000000000000030931039103)
Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012;156(12):861–74, W301–10. https://doi.org/10.7326/0003-4819-156-12-201206190-00436. (PMID: 10.7326/0003-4819-156-12-201206190-0043622711079)
Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–43. https://doi.org/10.1016/j.juro.2009.12.036 . (PMID: 10.1016/j.juro.2009.12.03620171677)
Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001–6. https://doi.org/10.1016/j.juro.2010.06.113 . (PMID: 10.1016/j.juro.2010.06.11320850833)
Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206–16. Available from: https://onlinelibrary.wiley.com/doi/10.1002/nau.22251. (PMID: 10.1002/nau.2225122581511)
Booth J, Connelly L, Dickson S, Duncan F, Lawrence M. The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: a systematic review. Neurourol Urodyn. 2018;37(2):528–41. https://doi.org/10.1002/nau.23351 . (PMID: 10.1002/nau.2335128731583)
Xia L, Yan H, Sun Y, et al. Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome. Medicine. 2021;100(45):e27745. https://doi.org/10.1097/MD.0000000000027745 . (PMID: 10.1097/MD.00000000000277453476658710545354)
Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–85. https://doi.org/10.1111/j.1742-1241.2010.02626.x . (PMID: 10.1111/j.1742-1241.2010.02626.x21489081)
Te Dorsthorst MJ, Heesakkers JPFA, van Balken MR. Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients. Neurourol Urodyn. 2020;39(2):702–6. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/nau.24254. (PMID: 10.1002/nau.24254)
Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194–201. https://doi.org/10.1016/j.juro.2012.11.175 . (PMID: 10.1016/j.juro.2012.11.17523219541)
Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol. 2014;6:1–16. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862648/.
Herrero-Zazo M, Berry R, Bines E, Bhattacharya D, Myint PK, Keevil VL. Anticholinergic burden in older adult inpatients: patterns from admission to discharge and associations with hospital outcomes. Ther Adv Drug Saf. 2021;6(12):20420986211012590. https://doi.org/10.1177/20420986211012592 . (PMID: 10.1177/20420986211012592)
Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;25(361):k1315. https://doi.org/10.1136/bmj.k1315 . (PMID: 10.1136/bmj.k1315)
Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084–93. https://doi.org/10.1001/jamainternmed.2019.0677 . (PMID: 10.1001/jamainternmed.2019.0677312330956593623)
Pieper NT, Grossi CM, Chan WY, Loke YK, Savva GM, Haroulis C, et al. Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis. Age Ageing. 2020;49(6):939–47. https://doi.org/10.1093/ageing/afaa090 . (PMID: 10.1093/ageing/afaa090326034157583519)
Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol. 2013;189(1):210–6. https://doi.org/10.1016/j.juro.2012.08.085 . (PMID: 10.1016/j.juro.2012.08.08523174264)
Vollstedt A, Gilleran J. Update on implantable PTNS devices. Curr Urol Rep. 2020;21(7):28. https://doi.org/10.1007/s11934-020-00980-5 . (PMID: 10.1007/s11934-020-00980-532462381)
Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–33. Available from: https://www.sciencedirect.com/science/article/pii/S030228381830201X. (PMID: 10.1016/j.eururo.2018.03.02029699858)
Chapple CR, Cruz F, Cardozo L, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77(1):119–28. https://doi.org/10.1016/j.eururo.2019.09.024 . (PMID: 10.1016/j.eururo.2019.09.02431635815)
Wielage RC, Perk S, Campbell NL, et al. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare advantage perspectives. J Med Econ. 2016;19(12):1135–43. https://doi.org/10.1080/13696998.2016.1204307 . (PMID: 10.1080/13696998.2016.120430727326725)
AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder. Female Pelvic Med Reconstr Surg. 2017;23(3):177–8. https://doi.org/10.1097/SPV.0000000000000423.
Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41(8):1928–33. https://doi.org/10.1002/nau.25037 . (PMID: 10.1002/nau.2503736066046)
Centers for Medicare & Medicaid Services. Posterior Tibial Nerve Stimulation (PTNS). Centers for Medicare & Medicaid services: Medicare coverage database. 2019. Available from: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33406&ver=10.
فهرسة مساهمة: Keywords: Anticholinergics; Incontinence; Nerve stimulation; Overactive bladder
المشرفين على المادة: 0 (Cholinergic Antagonists)
تواريخ الأحداث: Date Created: 20240503 Date Completed: 20240809 Latest Revision: 20240809
رمز التحديث: 20240809
DOI: 10.1007/s00192-024-05791-7
PMID: 38700729
قاعدة البيانات: MEDLINE
الوصف
تدمد:1433-3023
DOI:10.1007/s00192-024-05791-7